Arxis, Inc. (ARXS) is a dynamic biotechnology company focused on developing cutting-edge therapeutics for complex diseases, leveraging a robust research and development framework. With a diverse drug pipeline targeting both rare and widespread conditions, Arxis emphasizes strategic partnerships and comprehensive clinical initiatives to drive innovation and improve patient outcomes. As it progresses through critical clinical trial phases, the company is well-positioned for substantial growth and value creation, making it an attractive proposition for institutional investors in the fast-evolving biotech sector.
| Revenue (TTM) | $1.77B |
| Gross Profit (TTM) | $926.63M |
| EBITDA | $520.55M |
| Operating Margin | 6.53% |
| Return on Equity | 1.51% |
| Return on Assets | 2.89% |
| Revenue/Share (TTM) | $4.24 |
| Book Value | $10.70 |
| Price-to-Book | 4.93 |
| Price-to-Sales (TTM) | 13.10 |
| EV/Revenue | 13.1 |
| EV/EBITDA | 72.30 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 25.00% |
| Shares Outstanding | $90.15M |
| Float | $78.18M |
| % Insiders | 13.59% |
| % Institutions | 66.41% |
Volatility is currently expanding
BLOOMFIELD, Conn., Oct. 15, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) today announced that it will release its financial results for the third quarter of 2026 after the market closes on Wednesday, October 28, 2026.
BLOOMFIELD, Conn., Sept. 3, 2026 /PRNewswire/ -- Arxis, Inc. (Nasdaq: ARXS) (the "Company" or "Arxis"), a publicly traded industrial compounder formed in partnership with Arcline Investment Management ("Arcline"), today announced that it completed the acquisitions of Schatz Bearing Corporation ("Schatz") on September 2, 2026, and StratEdge Corporation ("StratEdge") on September 1, 2026.
BLOOMFIELD, Conn., Aug. 18, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) (the "Company" or "Arxis"), a publicly traded industrial compounder formed in partnership with Arcline Investment Management ("Arcline"), today announced that it has completed its previously announced acquisition of Omnetics Connector Corporation ("Omnetics").
Arxis, Inc. (ARXS) Q2 2026 Earnings Call Transcript
Arxis NASDAQ: ARXS reported second-quarter sales of $501 million, up 25% from a year earlier, as organic growth, pricing and acquisitions contributed to broad-based gains across its businesses and end markets.
BLOOMFIELD, Conn., July 29, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS)(the "Company" or "Arxis"), a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical engineered components, today reported financial results for the second quarter ended June 30, 2026.
BLOOMFIELD, Conn., July 16, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) today announced that it will release its financial results for the second quarter of 2026 after the market closes on Wednesday, July 29, 2026.
Arxis, Inc. (ARXS) Q1 2026 Earnings Call Transcript
BLOOMFIELD, Conn., June 2, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) (the "Company" or "Arxis"), a publicly-traded industrial compounder formed in partnership with Arcline Investment Management ("Arcline"), today announced it has entered into a definitive agreement to acquire Omnetics Connector Corporation ("Omnetics"), a leading designer and manufacturer of proprietary high-reliability Micro-D-Sub and Nano-D-Sub connectors and interconnect assemblies used in critical defense and space, commercial aerospace, and medical applications.
Arxis NASDAQ: ARXS reported a strong first quarter in its first earnings call as a public company, with management pointing to broad-based growth across defense and space, commercial aerospace and industrial technology, as well as a strengthened balance sheet following its initial public offering.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ARXS and any ticker you trade — then tracks every position and per-strategy win rate.
